|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.00 EUR | -5.15% |
|
-8.38% | -21.93% |
| Feb. 24 | Wedbush Initiates Abivax at Underperform With $110 Price Target | MT |
| Feb. 23 | Abivax Shows Jitters Despite Promising Updates on Obefazimod |  |
Company Valuation: Abivax
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 475.9 | 467.2 | 103.7 | 615.2 | 428.2 | 7,316 | 7,316 | - |
| Change | - | -1.83% | -77.81% | 493.46% | -30.4% | 1,608.74% | 0% | - |
| Enterprise Value (EV) 1 | 446.6 | 406.5 | 76.71 | 439.9 | 358.6 | 6,777 | 6,774 | 6,631 |
| Change | - | -8.99% | -81.13% | 473.44% | -18.49% | 1,790.15% | -0.05% | -2.11% |
| P/E ratio | -13.1x | -11.6x | -1.97x | -2.86x | -2.41x | -30.5x | -30x | -28.8x |
| PBR | - | 13.4x | 15.8x | 3.15x | 10.5x | 17.5x | 29.6x | 176x |
| PEG | - | 2.03x | -0.1x | -0.3x | 0.1x | -3x | -18.39x | -7.02x |
| Capitalization / Revenue | 280x | 48.2x | 1,037x | 134x | 34.3x | 1,309x | 223x | 50.5x |
| EV / Revenue | 263x | 41.9x | 767x | 95.6x | 28.7x | 1,212x | 206x | 45.8x |
| EV / EBITDA | -11.8x | -9.59x | -1.36x | -3.47x | -2.09x | -32.9x | -31.3x | -36.6x |
| EV / EBIT | -11.8x | -9.54x | -1.36x | -3.45x | -2.07x | -30.6x | -37.2x | -42.5x |
| EV / FCF | -14.5x | -8.59x | -1.16x | -4.52x | -2.32x | -38.9x | -164x | 360x |
| FCF Yield | -6.88% | -11.6% | -85.9% | -22.1% | -43.1% | -2.57% | -0.61% | 0.28% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.62 | -2.47 | -3.13 | -3.43 | -2.8 | -3.084 | -3.134 | -3.262 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1.7 | 9.7 | 0.1 | 4.6 | 12.5 | 5.59 | 32.85 | 144.8 |
| EBITDA 1 | -37.94 | -42.4 | -56.57 | -126.7 | -171.9 | -205.8 | -216.1 | -181.2 |
| EBIT 1 | -38 | -42.6 | -56.6 | -127.4 | -172.9 | -221.7 | -182 | -155.9 |
| Net income 1 | -37.6 | -41.4 | -69.8 | -147.4 | -176.2 | -270.9 | -193.7 | -166 |
| Net Debt 1 | -29.3 | -60.7 | -26.95 | -175.3 | -69.6 | -538.8 | -542 | -684.8 |
| Reference price 2 | 34.40 | 28.55 | 6.18 | 9.82 | 6.76 | 94.00 | 94.00 | 94.00 |
| Nbr of stocks (in thousands) | 13,834 | 16,363 | 16,774 | 62,646 | 63,336 | 77,830 | 77,830 | - |
| Announcement Date | 3/31/21 | 3/16/22 | 4/19/23 | 4/2/24 | 3/24/25 | - | - | - |
1EUR in Million2EUR
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -30.48x | 1212.46x | -32.93x | - | 8.49B | |
| 35.29x | 5.14x | 17.22x | 0.97% | 45.49B | |
| 54.35x | 4.68x | 31.54x | -.--% | 33.41B | |
| 56.43x | 11.55x | 32.31x | 0.34% | 31.32B | |
| 21.15x | 2.46x | 10.59x | -.--% | 29.29B | |
| -12.85x | 334.46x | -10.88x | -.--% | 19.5B | |
| 45.29x | 8.66x | 27.2x | -.--% | 14.77B | |
| 27.52x | 4.39x | 19.99x | -.--% | 13.36B | |
| 21.12x | 1.94x | 8.48x | 1.17% | 13.21B | |
| -18.31x | 14.28x | -19.9x | -.--% | 12.23B | |
| Average | 19.95x | 160.00x | 8.36x | 0.28% | 22.11B | |
| Weighted average by Cap. | 28.91x | 81.52x | 14.50x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ABVX Stock
- Valuation Abivax
Select your edition
All financial news and data tailored to specific country editions
